ReviewFumarate hydratase in cancer: A multifaceted tumour suppressor
Introduction
Oncogenesis is a multistep process during which cells acquire molecular features known as “Hallmarks of Cancer”, which pave the way to malignant transformation [1]. The reprogramming of cellular metabolism is now widely considered a pivotal hallmark of cancer that allows cancer cells to survive, proliferate, and metastasize [2]. Although added to the list of the hallmarks only recently [2], the first piece of evidence that cellular metabolism is reprogrammed in cancer was provided already in 1887 by Ernst Freund, a Viennese physician, who observed high sugar levels in the blood of cancer patients [3]. Based on this observation he proposed that reducing the amount of sugar could impact the tumour growth [3]. In 1911 the German scientist Wassermann postulated that accelerated proliferation of cancer cells was associated with an increased oxygen consumption [4]. To validate this hypothesis, he tried, without success though, to target tumours using inhibitors of respiration such as selenium derivates [4]. Just two years later, in 1913, Eleanor Van Ness Van Alstyne and colleagues showed that increased carbohydrate intake resulted in accelerated rat sarcoma growth [5], which was further confirmed by William Woglom in 1915 [6]. These works supported the notion that tumours use nutrients such as glucose and oxygen in a different way than normal tissue. A few years later, these findings were systematically investigated by Otto Warburg. He demonstrated that cancer cells ferment most of their glucose to lactate even in the presence of normal levels of oxygen when glucose should be fully oxidised to carbon dioxide through cellular respiration [7]. After the discovery that respiration is carried out by the mitochondria, Warburg concluded that all cancers must originate from a mitochondrial dysfunction [8].
After Warburg’s discoveries, the field of cancer metabolism was neglected until the beginning of the 21st century, when major discoveries and technical advances, including the advent of metabolomics, rekindled the field. Furthermore, thanks to the availability of large collections of gene expression data from cancer patients, the metabolic landscape of cancer could be extensively assessed using gene expression of metabolic enzymes. These bioinformatics analyses showed that both nuclear and mitochondrial DNA-encoded mitochondrial genes are suppressed in cancer [[9], [10], [11]] and this feature is associated with poor clinical outcome and metastasis [9]. Noteworthy, not all tumours exhibit mitochondrial impairment and it should be highlighted that the complete loss of mitochondrial function can be detrimental for cancer cells [12,13]. The role of mitochondrial dysfunction in cancer was further corroborated by recent sequencing efforts that led to the discovery that mitochondrial genes, including fumarate hydratase (FH), succinate dehydrogenase (SDH) and isocitrate dehydrogenase (IDH), when mutated, cause hereditary and sporadic forms of cancer (reviewed in [14]). Although these discoveries were made almost twenty years ago, the mechanisms underpinning transformation in these metabolically impaired tumours are still under intense investigation and could provide unique mechanistic insights into the link between dysregulated mitochondrial function and transformation. In this review, we will focus on the role of FH loss in cancerous transformation.
Section snippets
Fumarate Hydratase mutations in human diseases
In the human genome the gene encoding FH is located in the chromosome locus 1p43 and encompasses 22229 bases transcribing for 10 exons (NCBI database, NG_012338.1) that give rise to the FH monomer, which exhibits a “tridomain” structure, with a central domain involved in the interactions with the other monomers, an N-terminal Lyase 1 domain, and a C-terminal Fumarase C domain (Ensembl database, FH-001 ENST00000366560.3) (Fig. 1A). Interestingly, the FH gene encodes for both the cytosolic and
Metabolic rewiring in FH-deficient cells
The TCA cycle is a set of metabolic reactions within the mitochondria that represents the final converging route for the oxidation of lipids, carbohydrates, and amino acids [33]. Consequently, TCA cycle enzymes are essential for cell growth and survival, and it came as a surprise that FH loss could not only be tolerated by cells but that it could also cause cancer. Therefore, it was argued that FH-deficient cells must respond to this mitochondrial impairment by compensatory metabolic changes.
A possible paradigm of tumorigenesis in HLRCC
In the previous paragraphs of this review, we provided compelling evidence that upon FH loss cells orchestrate a multifaceted reprogramming that includes pro-survival metabolic adaptations and the activation of oncogenic cascades. However, the specific contribution of these signalling cascades towards cellular transformation is not fully understood. Based on our current understanding, we postulate that tumorigenesis driven by FH loss occurs via a series of steps over time, largely divided into
Competing interests
CF is a member of the scientific advisory board of Owlstone Medicals, Cambridge, UK and a scientific advisor for Istesso Limited, London, UK.
Authors’ contribution
CS, MS, and CF jointly wrote the manuscript.
Authors’ information and funding
CS is a PhD student and MS is a Research Associate in the laboratory of CF. CF is a group leader at the MRC Cancer Unit, University of Cambridge. MS and CF are funded by an MRC Core Funding to the MRC Cancer Unit MRC_MC_UU_12022/6; CS is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722605.
Acknowledegment
We thank all the members of the Frezza’s laboratory for insightful discussion.
References (108)
- et al.
The hallmarks of Cancer
Cell.
(2000) - et al.
Hallmarks of cancer: the next generation
Cell.
(2011) - et al.
The genomic landscape of renal oncocytoma identifies a metabolic barrier to tumorigenesis
Cell Rep.
(2015) - et al.
Oncometabolites: unconventional triggers of oncogenic signalling cascades
Free Radic. Biol. Med.
(2016) - et al.
Mitochondrial and cytosolic isoforms of yeast fumarase are derivatives of a single translation product and have identical amino termini
J. Biol. Chem.
(2001) - et al.
Fumaric aciduria a new organic aciduria associated with mental retardation and speech impairment
Clin. Chim. Acta
(1983) - et al.
Post-translational regulation of metabolism in fumarate hydratase deficient cancer cells
Metab. Eng.
(2018) - et al.
Mitochondrial membrane potential
Anal. Biochem.
(2018) - et al.
Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency
Cell Rep.
(2013) - et al.
A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia
Cell Rep.
(2013)
Fumarate hydratase loss causes combined respiratory chain defects
Cell Rep.
The structure of adenylosuccinate lyase, an enzyme with dual activity in the de novo purine biosynthetic pathway
Structure
Fumarate hydratase deletion in pancreatic beta cells leads to progressive diabetes
Cell Rep.
Metabolic synthetic lethality in cancer therapy
Biochim. Biophys. Acta
S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate
Arch. Biochem. Biophys.
Renal cyst formation in Fh1-Deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling
Cancer Cell
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma
Cancer Cell
Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth
Cancer Cell
Structural basis of Keap1 interactions with Nrf2, Free Radic
Biol. Med.
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling
Cancer Cell
NRF2 and the hallmarks of Cancer
Cancer Cell
Mammalian iron metabolism and its control by iron regulatory proteins
Biochim. Biophys. Acta - Mol. Cell Res.
The proto-oncometabolite fumarate binds glutathione to amplify ROS-Dependent signaling
Mol. Cell
HIF-1alpha pathway: role, regulation and intervention for cancer therapy
Acta Pharm. Sin. B
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability
Cancer Cell
Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates
J. Biol. Chem.
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia
Cell Metab.
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Cell Metab.
Jumonji histone demethylases as emerging therapeutic targets
Pharmacol. Res.
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels
Cancer Cell
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer
Cancer Cell
Beiträge zum problem: Geschwülste von der blutbahn aus therapeutisch zu beeinflussen, Dtsch
Medizinische Wochenzeitschrift.
Diet studies in transplantable tumors : I. The effect of non-carbohydrate diet upon the growth of transplantable sarcoma in rats
J. Med. Res.
Diet and tumor growth
J. Exp. Med.
Über den Stoffwechsel der Carcinomzelle
Biochem Zeitschr.
On the origin of Cancer cells
Science
Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival
Nat. Commun.
Mitochondrial DNA copy number variation across human cancers
Elife.
Mitochondrial respiratory gene expression is suppressed in many cancers
Elife.
Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient Cancer cells
Cell Metab.
Structural basis of fumarate hydratase deficiency
J. Inherit. Metab. Dis.
Fumarase: a paradigm of dual targeting and dual localized functions
FEBS J.
Human fumarate hydratase is dual localized by an alternative transcription initiation mechanism
Traffic.
Mitochondrial metabolites: undercover signalling molecules
Interface Focus
Fumaric aciduria: an overview and the first Brazilian case report
J. Inherit. Metab. Dis.
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
Nat. Genet.
Hereditary leiomyomatosis and renal cell carcinoma
Int J Nephrol Renov. Dis.
Cited by (91)
Mitochondrial metabolism as a dynamic regulatory hub to malignant transformation and anti-cancer drug resistance
2024, Biochemical and Biophysical Research CommunicationsResearch progress on the pathogenesis of the SDHB mutation and related diseases
2023, Biomedicine and PharmacotherapyFOXA2 controls the anti-oxidant response in FH-deficient cells
2023, Cell ReportsFumarate disarms CD8<sup>+</sup> T cells against cancer
2023, Cell Metabolism